Abstract
The use of general anaesthetics has facilitated great advantages in surgery within the last 150 years. General anaesthesia is composed of several components including analgesia, amnesia, hypnosis and immobility. To achieve these components, general anaesthetics have to act via multiple molecular targets at different anatomical sites in the central nervous system. Much of our current understanding of how anaesthetics work has been obtained within the last few years on the basis of genetic approaches, in particular knock-out or knock-in mice. Anaesthetic drugs can be grouped into volatile and intravenous anaesthetics according to their route of administration. Common volatile anaesthetics induce immobility via molecular targets in the spinal cord, including glycine receptors, GABAA receptors, glutamate receptors, and TREK-1 potassium channels. In contrast, intravenous anaesthetics cause immobility almost exclusively via GABAA receptors harbouring β3 subunits. Hypnosis is predominantly mediated by β3-subunit containing GABAA receptors in the brain, whereas β2 subunit containing receptors, which make up more than 50% of all GABAA receptors in the central nervous system, mediate sedation. At clinically relevant concentrations, ketamine and nitrous oxide block NMDA receptors. Unlike all other anaesthetics in clinical use they produce analgesia. Not only desired actions of anaesthetics, but also undesired side effects are linked to certain receptors. Respiratory depression involves β3 containing GABAA receptors whereas hypothermia is largely mediated by GABAA receptors containing β2 subunits. These recent insights into the clinically desired and undesired actions of anaesthetic agents provide new avenues for the design of drugs with an improved side-effect profile. Such agents would be especially beneficial for the treatment of newborn children, elderly patients and patients undergoing ambulatory surgery.
Keywords: Meyer-Overton correlation, Ligand gated ion channels, Synaptic Transmission, immobility, Sedation, NMDA receptors
Current Pharmaceutical Design
Title: Anaesthetic Drugs: Linking Molecular Actions to Clinical Effects
Volume: 12 Issue: 28
Author(s): Christian Grasshoff, Berthold Drexler, Uwe Rudolph and Bernd Antkowiak
Affiliation:
Keywords: Meyer-Overton correlation, Ligand gated ion channels, Synaptic Transmission, immobility, Sedation, NMDA receptors
Abstract: The use of general anaesthetics has facilitated great advantages in surgery within the last 150 years. General anaesthesia is composed of several components including analgesia, amnesia, hypnosis and immobility. To achieve these components, general anaesthetics have to act via multiple molecular targets at different anatomical sites in the central nervous system. Much of our current understanding of how anaesthetics work has been obtained within the last few years on the basis of genetic approaches, in particular knock-out or knock-in mice. Anaesthetic drugs can be grouped into volatile and intravenous anaesthetics according to their route of administration. Common volatile anaesthetics induce immobility via molecular targets in the spinal cord, including glycine receptors, GABAA receptors, glutamate receptors, and TREK-1 potassium channels. In contrast, intravenous anaesthetics cause immobility almost exclusively via GABAA receptors harbouring β3 subunits. Hypnosis is predominantly mediated by β3-subunit containing GABAA receptors in the brain, whereas β2 subunit containing receptors, which make up more than 50% of all GABAA receptors in the central nervous system, mediate sedation. At clinically relevant concentrations, ketamine and nitrous oxide block NMDA receptors. Unlike all other anaesthetics in clinical use they produce analgesia. Not only desired actions of anaesthetics, but also undesired side effects are linked to certain receptors. Respiratory depression involves β3 containing GABAA receptors whereas hypothermia is largely mediated by GABAA receptors containing β2 subunits. These recent insights into the clinically desired and undesired actions of anaesthetic agents provide new avenues for the design of drugs with an improved side-effect profile. Such agents would be especially beneficial for the treatment of newborn children, elderly patients and patients undergoing ambulatory surgery.
Export Options
About this article
Cite this article as:
Grasshoff Christian, Drexler Berthold, Rudolph Uwe and Antkowiak Bernd, Anaesthetic Drugs: Linking Molecular Actions to Clinical Effects, Current Pharmaceutical Design 2006; 12 (28) . https://dx.doi.org/10.2174/138161206778522038
DOI https://dx.doi.org/10.2174/138161206778522038 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Selective Agonists and Antagonists for Kainate Receptors
Mini-Reviews in Medicinal Chemistry Preface:
Central Nervous System Agents in Medicinal Chemistry Microarrays in Brain Research: Data Quality and Limitations Revisited
Current Genomics Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: Endocrine Disorders and Cognitive Function in the Elderly)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
Current Drug Targets Depression and Disturbed Bone Metabolism: A Narrative Review of the Epidemiological Findings and Postulated Mechanisms
Current Molecular Medicine New Strategies for Immune-Mediated Anti-Viral Drug and Vaccine Development
Current Pharmaceutical Design A Single Use Biosensor for the Detection of Nitric Oxide (NO) at ppb and sub-μM Level in Gas-and Liquid- Phase Media
Current Biomarkers (Discontinued) Systems Genomics Support for Immune and Inflammation Hypothesis of Depression
Current Neuropharmacology Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Diet and Neurocognition: Review of Evidence and Methodological Considerations
Current Aging Science Methotrexate-Induced Pneumonitis: Heterogeneity of Bronchoalveolar Lavage and Differences between Cancer and Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Medical Management of Obesity
Current Nutrition & Food Science Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
Current Drug Targets Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design